Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Tiziana Life Sciences: Expansion into new clinical indications - Proactive Research Analyst

Tiziana Life Sciences PLC

Proactive research analyst Robin Davison speaks to Thomas Warner after publishing a new research note on clinical-stage biopharmaceutical company Tiziana Life Sciences Ltd (NASDAQ:TLSA). Tiziana has disclosed plans to file INDs (Investigational New Drug applications) aiming to expand the clinical indications of its lead product, intranasal foralumab, into mild-to-moderate Alzheimer’s Disease (AD) and long COVID-19. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

May 05, 2023 10:49 AM Eastern Daylight Time

Video

GBB Drink Lab Files $53M Lawsuit Against FSD Pharma for Nondisclosure Contract Breach and Trade Secret Misappropriation

GBB Drink Lab

GBB Drink Lab (“GBB” or the “Company”), maker of the world’s first formulated drink that aids in rapid blood alcohol detoxification, has announced that the Company has filed a lawsuit against FSD Pharma (NASDAQ: HUGE) (“FSD”), a publicly traded biotechnology company that operates in the pharmaceutical research and development business. As a result of FSD Pharma’s failure to comply with a Cease-and-Desist letter sent by GBB on April 14 th, 2023, the Company has subsequently filed a $53 million complaint for material breach of a mutual nondisclosure agreement and trade secret misappropriation. Filed on May 1 st, 2023, in the U.S. District Court for the Southern District of Florida, the complaint alleges that after seven months of exploring a business opportunity of mutual interest and benefit revolving around GBB’s blood alcohol detoxification drink, FSD Pharma publicly announced the misappropriation of GBB’s trade secrets to current and prospective investors in one of its press releases. In the press release, FSD Pharma discussed the launch of a new research and development program targeting unmet medical needs for alcohol misuse and deliberately omitted the underlying misappropriation. GBB’s lawsuit alleges that FSD Pharma used GBB’s proprietary and confidential material to raise capital, persuade iconic entrepreneurs to join its advisory board, and drive up the price of FSD Pharma’s publicly traded stock. The Company is seeking compensatory and punitive damages as well as an injunction against FSD Pharma preventing further unlawful disclosure and use of the Company’s trade secrets. The lawsuit has been filed in the U.S. District Court for the Southern District of Florida under the name GBB DRINK LAB, INC. v. FSD BIOSCIENCES INC. with case number: 0:23-cv-60800-AHS. GBB has a patented formula that accelerates the process of converting alcohol to sugar in the body. By enhancing the metabolic pathways that facilitate this process, the formula can help the body clear alcohol much faster than normal. The Company has been working on a proprietary drink for several years using its patented formula. About GBB Drink Lab GBB Drink Lab started with a vision of making a positive impact by offering practical, evidence-based solution to reducing Blood Alcohol Content. The company’s product has been meticulously crafted to optimize your ability to sober up thus enabling you to escape an inebriated state. GBB Drink Lab leadership team includes accomplished serial entrepreneurs, a former senior executive from one of the world’s largest beverage companies, and an industry-leading expert in flavoring science and product formulation. For more information, visit https://gbbdrinklab.com/. Media Contact Jarrett Boon Co-Founder, CEO, GBB Drink Lab, Inc Jarrett@gbbdrinklab.com 602-456-1555 Contact Details GBB Drink Lab Jarrett@gbbdrinklab.com Company Website https://gbbdrinklab.com/

May 05, 2023 08:45 AM Eastern Daylight Time

News Release

1606 Corp launches marketing campaign for CBD singles as it fills gap left by menthol tobacco ban

1606 Corp.

1606 Corp CEO Greg Lambrecht joins Proactive's Stephen Gunnion with details of the company's first major marketing campaign of 2023 focused on menthol-flavored tobacco alternatives in California to address the demand for menthol-flavored smokables following the state’s ban on menthol-flavored tobacco. He says the multi-channel direct marketing campaign, labelled ‘Cali Push,’ is targeted at California merchants, convenience stores, gas stations, liquor stores, and smoke shops which previously stocked menthol-flavored products. The company has enough inventory to place menthol replacement products in more than 2,000 stores immediately, he adds. Contact Details Proactive Investors +1 347-449-0879 na-editorial@proactiveinvestors.com

May 04, 2023 01:25 PM Eastern Daylight Time

Video

News Release

OKYO Pharma reaches milestone with first patient screening for dry eye disease trial

OKYO Pharma Ltd

OKYO Pharma Ltd CEO Gary Jacob tells Proactive's Stephen Gunnion that the first patient has been screened for the phase II trial of OK-101, a treatment for dry eye disease (DED), marking a significant step for the company. Jacob says the phase II trials aims to evaluate the drug's efficacy and safety in DED patients, with top-line data expected before the end of 2023. If successful, he said the phase II assessment could also serve as one of the two required phase III studies necessary for US Food & Drug Administration (FDA) approval. Contact Details Proactive Investors +1 347-449-0879 na-editorial@proactiveinvestors.com

May 04, 2023 01:22 PM Eastern Daylight Time

Video

Bryan Keeven Promoted to Senior Vice President of AmeriLife Health Distribution

AmeriLife

AmeriLife Group, LLC (“AmeriLife”), a national leader in developing, marketing, and distributing life and health insurance, annuities and retirement planning solutions, today announced the promotion of Bryan Keeven to the role of senior vice president, Health Distribution. In this newly created role, Keeven will expand his oversight to include all affiliates in the company’s Health organization. His strategic focus will be providing servant leadership to achieve top- and bottom-line financial objectives. Keeven’s promotion follows a series of organizational changes focused on fortifying AmeriLife’s fast-growing health and life distribution business. The strategic, organizational structuring continues to take shape following three years of record-breaking growth and expansion. Scotty Elliott, chief distribution officer, Health, announced the appointment. “Bryan’s contributions to strengthen AmeriLife’s Health Distribution continue to make a significant impact for our partners across our distribution affiliates,” said Elliott. “His focused leadership fuels the strategic momentum we’ve created as a company. We are excited to enable further growth and focus for our VP levels and talented affiliates to better serve our business and customers.” Keeven, who has more than 25 years of experience in the insurance and Medicare industry, most recently served as Vice President, Life & Health, where he worked directly with AmeriLife’s portfolio of affiliates and Vice President of Managed Care Sales where he strengthened the online agent and marketer YourMedicare.com platform. Before AmeriLife, he was National Vice President of Sales for Medicare & Marketplace for Molina Healthcare. He also previously served in senior leadership roles with Bloom Insurance Agency, Aetna, and Coventry Health Care. Keeven is a licensed insurance agent and holds a bachelor’s degree in Health/Health Care Administration/Management from Southeast Missouri State University and an MBA from Lindenwood University. “AmeriLife’s continued alignment to trailblaze and optimize leadership capabilities is impressive and I am thankful and excited to take this next step,” added Keeven. “Team building and culture development that foster greater collaboration and effectiveness is at the heart of AmeriLife’s Health Distribution, and a continued tenet of focus going forward.” Keeven’s appointment is another strategic move to support AmeriLife’s recent restructuring of the company’s Distribution organization that creates distinct Wealth and Health groups, streamlining company expertise to meet the growing demands of the market, AmeriLife’s affiliated companies, and their agents and advisors. ### About AmeriLife AmeriLife’s strength is its mission: to provide insurance and retirement solutions to help people live longer, healthier lives. In doing so, AmeriLife has become recognized as the leader in developing, marketing, and distributing life and health insurance, annuities and retirement planning solutions to enhance the lives of pre-retirees and retirees across the United States. For more than 50 years, AmeriLife has partnered with top insurance carriers to provide value and quality to customers served through a distribution network of over 300,000 insurance agents and advisors and 120 marketing organizations and insurance agency locations nationwide. For more information, visit AmeriLife.com, and follow AmeriLife on Facebook and LinkedIn. Contact Details Media Jeff Maldonado +1 321-297-1112 jmaldonado@amerilife.com Partnership Inquiries Patrick Nichols +1 727-726-0726 pnichols@amerilife.com Company Website https://amerilife.com/

May 04, 2023 01:00 PM Eastern Daylight Time

News Release

Greenlink International announces launch of Suncliff CBD-infused pillow

Greenlink International

Greenlink International CEO Jake George joined Steve Darling from Proactive to share news the company has launched its Suncliff CBD-infused pillow in collaboration with Purecare. George tells Proactive this unique collection features five luxury pillows that incorporate microencapsulated CBD in the fabric, along with a complementary lavender CBD bedding mist to create what they say is a soothing sleep environment. The pillow will be available online and select retail locations in the US in May 2023. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

May 04, 2023 12:42 PM Eastern Daylight Time

Video

CleverTap appoints Benjamin Roodman as Vice President, Partnerships, North America

CleverTap

CleverTap, the all-in-one engagement platform, named Benjamin Roodman as Vice President, Partnerships for North America. In his new role, Benjamin will lead CleverTap’s channel and technical partner strategy – developing and managing relationships to drive CleverTap’s growth within the region. With over two decades of experience across the board, Benjamin has spent the past 13 years strengthening relations with business and channel partners. His appointment will help CleverTap build a more fruitful partner ecosystem within North America and further cement their position as market leaders in the region. Benjamin joins CleverTap from AppsFlyer where he was the AVP of Business Development. In his previous roles he has led partnerships across mobile SaaS, digital advertising, and cloud platforms. He is well versed in mobile growth platforms with a notable aptitude for analytics. “We are thrilled to have Benjamin on board. With the wealth of knowledge and experience he brings to the team, he will help drive growth in North America – a key-market for us.” said Momchil Kyurkchiev, Chief Strategy Officer at CleverTap. “Our channel and technical partners are an integral part of our growth strategy. To establish a robust partner ecosystem, it is crucial to collaborate with them and incorporate tools that offer innovative solutions to unanticipated issues. I am confident that with Benjamin’s appointment we will continue to build a world-class partner ecosystem and drive value for our customers.” “I am ecstatic to embark on this new journey and make a measured impact with CleverTap. A strong foundation in North America, and a burgeoning partner ecosystem, are a testament of CleverTap’s commitment within the region. At CleverTap, we understand the importance of building a robust partner network to further penetrate markets and provide exceptional service to our customers.” said Benjamin. “I look forward to working closely with our partners to develop innovative solutions that meet the evolving needs of our customers and accelerate their success. Together we will continue to drive innovation, foster collaboration, and build a stronger base for our expansion.” About CleverTap CleverTap is the all-in-one customer engagement platform that helps brands personalize and optimize all consumer touch points to improve user engagement, retention, and lifetime value. It's the only solution built to address the needs of retention and growth teams, with audience analytics, deep-segmentation, multi-channel engagement, product recommendations, and automation in one unified product. The platform is powered by TesseractDB™ – the world’s first purpose-built database for customer engagement, offering both speed and economies of scale. CleverTap is trusted by 2000 customers, including Electronic Arts, TiltingPoint, Gamebasics, Big Fish, MobilityWare, TED, English Premier League, TD Bank, Carousell, AirAsia, Papa John’s, and Tesco. Backed by leading investors such as Sequoia India, Tiger Global, Accel, and CDPQ the company is headquartered in Mountain View, California, with presence in San Francisco, New York, São Paulo, Bogota, London, Amsterdam, Sofia, Dubai, Mumbai, Singapore, and Jakarta. For more information, visit clevertap.com or follow on LinkedIn and Twitter. Forward-Looking Statements Some of the statements in this press release may represent CleverTap's belief in connection with future events and may be forward-looking statements, or statements of future expectations based on currently available information. CleverTap cautions that such statements are naturally subject to risks and uncertainties that could result in the actual outcome being absolutely different from the results anticipated by the statements mentioned in the press release. Factors such as the development of general economic conditions affecting our business, future market conditions, our ability to maintain cost advantages, uncertainty with respect to earnings, corporate actions, client concentration, reduced demand, liability or damages in our service contracts, unusual catastrophic loss events, war, political instability, changes in government policies or laws, legal restrictions impacting our business, impact of pandemic, epidemic, any natural calamity and other factors that are naturally beyond our control, changes in the capital markets and other circumstances may cause the actual events or results to be materially different, from those anticipated by such statements. CleverTap does not make any representation or warranty, express or implied, as to the accuracy, completeness or updated or revised status of such statements. Therefore, in no case whatsoever will CleverTap and its affiliate companies be liable to anyone for any decision made or action taken in conjunction. Contact Details Sony Shetty sony@clevertap.com Company Website https://clevertap.com/

May 04, 2023 07:00 AM Pacific Daylight Time

Emergent Health to spin out subsidiary PharmaZu to its Shareholders pursuant to an IPO underwritten by a Nationally Recognized Investment Banking Firm

Emergent Health Corp.

Emergent Health Corp. (OTC: EMGE), a curator, developer, and marketer of products in the Regenerative Health Space announced today that it has executed a Term Sheet for a firm committed underwriting with a nationally recognized investment banking firm for $10,000,000 with respect to planned corporate financing transactions, including the private placement of securities (“pre-IPO Financings”) and the planned $10 million initial public offering of Emergent subsidiary PharmaZu common stock (“IPO”) that will be applied for listing on NASDAQ or NYSE/AMEX, with NO DILUTION to Emergent shareholders. PharmaZu is a pure play, e-commerce products and service provider focused on the Pet Community, Pet Pharmacy and Pet Wellness using Influencers and their content, including pet pharmacy, vet telehealth and pet wellness businesses. Upon the effectiveness of the IPO and listing on a national exchange, PharmaZu plans to acquire a 48-state authorized compounding pharmacy located in West Palm Beach, FL, doing approximately $10M a year in revenue, which will serve as the backbone and fulfilment center for PharmaZu, creating a national platform throughout the United States. Subsequently, Emergent plans to distribute to its shareholders, pro rata, the shares of PharmaZu as a dividend, when a record date is set. The raise of capital will be used for expanding PharmaZu’s business, product offerings, as well as for acquisitions. Jim Morrison, former L'Oréal President and Emergents full time CEO stated, “The transaction with Boustead will start a new exciting chapter for PharmaZu, while maximizing the value to Emergent’s shareholders.” Adam Books, President of PharmaZu stated, “PharmaZu is poised to start its disrupting of the mail order pet business and pet medications, as well as advancing the tele-pet med environment. I am very thrilled to be a part of this.” The execution of the Engagement Letter does not constitute a commitment by Boustead or the Company to consummate any transaction contemplated hereunder and does not ensure the successful placement of securities of any investment vehicle or the success of Boustead with respect to finding any investors or the success with respect to any transaction. No promises, representations or guarantees have been made. ABOUT EMERGENT HEALTH CORPORATION Emergent curates, develops and sells products in the Regenerative Health Space. Its products comprise of ingestibles as well as topicals for the whole family. The company distributes its products online and through Content Based Shopping using Influencers to position products in their produced content throughout the United States and Internationally. Its subsidiaries; PharmaZu, is a pure play, e-commerce products and service provider focused on the Pet Community, Pet Pharmacy and Pet Wellness using Influencers and their content, including the pet pharmacy, vet telehealth and pet wellness businesses; Regen BioWellness, is a distributor of various products in the plant-based and regenerative medical fields. Evolutionary Biologics, is a new kind of biologics company founded for a clear purpose: bring cutting edge regenerative products to the medical community. Emergent does not claim any of its products are approved by the FDA to diagnose, treat, cure or prevent any disease. For more information, please visit Emergent's Website and Social Media on Twitter. Before using any products, you should always consult with your Veterinarian and/or Family Doctor. SAFE HARBOR STATEMENT This press release contains forward-looking statements that can be identified by terminology such as “believes,” “expects,” “potential,” “plans,” “suggests,” “may,” “should,” “could,” “intends,” or similar expressions. Many forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results implied by such statements. These factors include, but are not limited to, our ability to continue to enhance our products and systems to address industry changes, our ability to expand our customer base and retain existing customers, our ability to effectively compete in our market segment, the lack of public information on our company, our ability to raise sufficient capital to fund our business, operations, our ability to continue as a going concern, and a limited public market for our common stock, among other risks. Many factors are difficult to predict accurately and are generally beyond the company's control. Forward-looking statements speak only as to the date they are made, and we do not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made. FOR MORE INFORMATION, PLEASE CONTACT: Jim Morrison, CEO Emergent Health Corporation Website info@emergenthealthcompany.com Contact Details Emergent Health Corp. info@emergenthealthcompany.com Company Website https://emergenthealthcompany.com/

May 04, 2023 09:00 AM Eastern Daylight Time

Image

Hong Kong Baptist University joint research suggests that urine cytomegalovirus test facilitates early prediction of AIDS end-organ diseases

Hong Kong Baptist University

HONG KONG SAR - Media OutReach - 4 May 2023 - A Hong Kong Baptist University (HKBU) collaborative research team has shown that urine tests for human cytomegalovirus (HCMV) can identify the risk of end-organ diseases such as pneumonitis, gastrointestinal ulcers, hepatitis and myocarditis, earlier in patients who have been infected with human immunodeficiency virus type 1 (HIV-1). The findings suggest that HCMV detection in urine should be implemented as a routine test for HIV-1 patients who are progressing towards acquired immunodeficiency syndrome (AIDS), as anti-HCMV treatments could reduce the incidence of lung and cardiovascular end-organ diseases by half. The research findings have been published in the Journal of Clinical Virology, an international scientific journal. No routine HCMV check-ups for HIV-1 patients HIV-1 infection is divided into four clinical stages. In the first stage, patients are infected and some experience mild illnesses such as a cold without any apparent symptoms. HIV-1 infection then slowly progresses towards AIDS in the second and third stages of infection. These two stages, collectively regarded as the "developing" stage, usually last several years if they are comprehensively controlled by a range of medications before developing into AIDS, which represents the fourth stage of HIV-1 infection. HCMV is a DNA virus found in more than half of the human population. It is controlled by an intact immune system and remains dormant in healthy individuals. However, it can be reactivated in patients with poor immune systems, such as those in the fourth stage of HIV-1 infection, and as a result it can become one of the major opportunistic infections that cause life-threatening end-organ diseases. In Hong Kong, HCMV detection is not part of the routine check-ups for HIV-1 patients unless they suffer from apparent end-organ diseases. In such cases, blood tests are the preferred method of detection. A research team co-led by Dr Allen Cheung Ka-loon, Assistant Professor of the Department of Biology at HKBU, and Professor Chen Zhiwei, Professor of the Department of Microbiology, LKS Faculty of Medicine at the University of Hong Kong, in collaboration with researchers from the Third People's Hospital of Shenzhen, investigated the detection of HCMV in urine for the continuous monitoring of end-organ disease risk in HIV-1 patients. They also examined the relationship between HCMV detection and end-organ diseases in HIV-1 patients in the "developing" stage. Easier to detect HCMV in urine than in blood The team screened the records of more than 130,000 HIV-1 patients in Shenzhen between January 2011 and June 2022, and selected about 13,700 patients with relevant blood and urine test records. They were grouped according to the four stages of HIV-1 infection, and the results of their HCMV blood and urine tests were then compared. It was discovered that in all the four patient groups, the proportions of patients found to be HCMV-positive were higher in the urine samples than in the corresponding blood samples. The situation was particularly obvious for HIV-1 patients in the "developing" stage. Urine tests showed that 5.8% of second-stage HIV-1 patients were HCMV-positive compared to only 0.9% using blood tests. The proportions of third-stage HIV-1 patients found to be HCMV-positive using urine and blood tests were 12.8% and 1.4%, respectively. This suggests that HCMV is more easily detected in urine than in the blood, especially during the "developing" stage of HIV-1 infection. The researchers further filtered 233 "developing" stage HIV-1 patients with detailed clinical and disease records to evaluate the association between HCMV and the onset of different types of end-organ diseases. Statistical analysis revealed that there is a significant association between the incidence of lung and cardiovascular end-organ diseases and the detection of HCMV in urine. Early anti-HCMV treatment lowers the risk of end-organ diseases To study the effect of early interventions with anti-HCMV treatments, the team tracked the data of 54 "developing" stage HIV-1 patients who had been hospitalised at least once. They were divided into three groups: those who received no anti-HCMV treatments, those who received treatments but not during each round of hospitalisation, and those who received treatments during all rounds of hospitalisation. The data showed that those who received anti-HCMV treatments in all rounds of hospitalisation had the lowest incidence of lung and cardiovascular end-organ diseases. Furthermore, compared to those who had not received anti-HCMV treatments, the incidence of such end-organ diseases in patients who had received the treatments was reduced by half. This suggests that continuous anti-HCMV treatments are effective in reducing the onset of lung and cardiovascular end-organ diseases in patients who are progressing towards AIDS. Dr Allen Cheung said: "Patients have to face a difficult journey once they have tested positive for HIV. They are often at risk of developing end-organ diseases without any apparent symptoms. Our study shows that routine urine tests for HCMV can monitor the development of end-organ diseases more effectively, which signals the need for early medical intervention. We thus recommend that HCMV detection in urine should be implemented as a routine test for HIV-1 patients." Contact Details Communication and Public Relations Office, HKBU Winnie Shum hkbunews@hkbu.edu.hk

May 04, 2023 09:00 AM Eastern Daylight Time

Image

1 ... 109 110 111 112 113 ... 286